{
    "clinical_study": {
        "@rank": "57041", 
        "arm_group": {
            "arm_group_label": "Oxytocin", 
            "arm_group_type": "Experimental", 
            "description": "Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks."
        }, 
        "brief_summary": {
            "textblock": "This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a\n      treatment for social impairment in adolescents with autism spectrum disorders (ASD). We\n      hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving\n      the core symptoms of autism spectrum disorders in adolescents ages 11-17."
        }, 
        "brief_title": "An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Autism Spectrum Disorders", 
            "Pervasive Developmental Disorders", 
            "ASD", 
            "PDD"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Developmental Disabilities", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female outpatients ages 11-17 years\n\n          2. DSM-IV-TR Pervasive developmental disorder (PDD) diagnosis of autistic disorder,\n             Asperger's disorder, or PDD Not Otherwise Specified (PDD-NOS) as established by\n             clinical diagnostic interview and with the aid of the MGH ASD Symptom Checklist\n             (MGH-ASD-SCL).\n\n          3. At least moderate severity of ASD impairment as measured by a raw score of \u226580 on the\n             SRS and a severity score of \u22654 on CGI-PDD.\n\n          4. Participants and their parent/guardian must be able to speak and understand English\n             sufficiently to comprehend the nature of the study and to allow for the completion of\n             all study procedures required per protocol.\n\n          5. Subjects and their parent/guardian must be considered reliable reporters.\n\n          6. Each subject and their parent/guardian must understand the nature of the study and\n             provide written informed assent/consent.\n\n          7. Subjects must be able to participate in mandatory blood draws.\n\n          8. Subjects with mood, anxiety, or disruptive behavior disorders will be allowed to\n             participate in the study provided they do not meet any exclusionary criteria.\n\n        Exclusion Criteria:\n\n          1. Intelligence Quotient (IQ) <85\n\n          2. Total lack of spoken language\n\n          3. DSM-IV-TR PDD (Pervasive Developmental Disorder) diagnosis of Rett's disorder or\n             childhood disintegrative disorder.\n\n          4. Clinically unstable psychiatric conditions or judged to be at serious suicidal risk\n             as determined by evaluating investigator.\n\n          5. History of substance use (except nicotine or caffeine) within past 3 months\n\n          6. Serious, stable or unstable systemic illness including hepatic, renal,\n             gastroenterological, respiratory, cardiovascular (including ischemic heart disease),\n             endocrinologic, neurologic, immunologic, or hematologic disease.\n\n          7. Subjects with severe hepatic impairment (Liver function tests > 3 times upper limit\n             of normal) and those with severely impaired renal function (eGFR < 30).\n\n          8. Pregnant or nursing females.\n\n          9. Known hypersensitivity to oxytocin.\n\n         10. Severe allergies or multiple adverse drug reactions.\n\n         11. A non-responder or history of intolerance to oxytocin, after treatment at adequate\n             doses as determined by the clinician.\n\n         12. Investigator and his/her immediate family defined as the investigator's spouse,\n             parent, child, grandparent, or grandchild."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "11 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931033", 
            "org_study_id": "2013-P-001548"
        }, 
        "intervention": {
            "arm_group_label": "Oxytocin", 
            "intervention_name": "Intranasal Oxytocin", 
            "intervention_type": "Drug", 
            "other_name": "Syntocinon"
        }, 
        "intervention_browse": {
            "mesh_term": "Oxytocin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Autism Spectrum Disorders", 
            "Pervasive Developmental Disorders", 
            "ASD", 
            "PDD", 
            "Oxytocin", 
            "Syntocinon", 
            "treatment"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "email": "Sfurtak1@partners.org", 
                "last_name": "Stephannie Furtak", 
                "phone": "617-724-2344"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Gagan Joshi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders", 
        "overall_contact": {
            "email": "sfurtak1@partners.org", 
            "last_name": "Stephannie Furtak", 
            "phone": "617-724-2344"
        }, 
        "overall_contact_backup": {
            "email": "Rgossman1@partners.org", 
            "last_name": "Rebecca Grossman", 
            "phone": "617-643-1432"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Gagan Joshi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A 65-item rating scale completed by the secondary reporter used to measure the severity of autism spectrum symptoms as they occur in natural settings.", 
            "measure": "Social Responsiveness Scale (SRS-2)", 
            "safety_issue": "No", 
            "time_frame": "Week-8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931033"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Gagan Joshi, MD", 
            "investigator_title": "Medical Director, Bressler Program for Autism Spectrum Disorders", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The CGI is a measure of illness severity, improvement, and efficacy of treatment (National Institute of Mental Health, 1985). The score for Improvement ranges from 1 (very much improved) to 7 (very much worse).", 
            "measure": "Clinical Global Impression of PDD - Improvement (CGI-I)", 
            "safety_issue": "No", 
            "time_frame": "Week-8"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}